Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Abstract

Conventionally, atherogenic dyslipidemias have been defined by elevated levels of triglyceride and/or LDL cholesterol. However, cholesterol and triglycerides are not metabolically and physically independent entities. Rather, they are constituents of the atherogenic apolipoprotein B (apoB) particles, which differ in their origin and their metabolic function. Moreover, the risk of vascular disease is not related to the plasma concentration of cholesterol or triglyceride per se, but to the number, composition and size of the apoB particles, within which the cholesterol and triglycerides are contained. After all, the entire apoB particle--rather than individual cholesterol or triglyceride molecules--enters and is trapped within the arterial wall, and this particle initiates and sustains the process that results in atherosclerosis. Accordingly, we suggest a change of name and focus from dyslipidemias to dyslipoproteinemias. Virtually all the atherogenic apoB dyslipoproteinemias can be specifically identified on the basis of plasma levels of cholesterol, triglyceride and apoB. Not only does this enable an accurate diagnosis in the individual, but the major familial dyslipoproteinemias can be identified as well. Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids.